Incyte Corp. Common Stock INCY
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T16:42:10.654Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T16:42:02.77035462Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T16:37:20.349409+00:00
Incyte Corp. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 115.16 | 57.0% | 7.5% | |||
| 25Δ | 129.78 | 48.9% | 6.4% | 116.81 | 54.9% | 6.4% |
| 30Δ | 128.51 | 49.1% | 5.7% | 118.45 | 52.8% | 5.4% |
| 35Δ | 127.24 | 49.3% | 5.0% | 120.06 | 50.7% | 4.4% |
| 40Δ | 125.97 | 49.5% | 4.3% | 121.19 | 49.6% | 3.8% |
| 45Δ | 124.74 | 49.4% | 3.7% | 122.31 | 48.5% | 3.3% |
| 50Δ | 123.64 | 48.5% | 3.2% | 123.44 | 47.3% | 2.8% |
| 55Δ | 122.55 | 47.7% | 2.7% | 124.57 | 46.2% | 2.2% |
| 60Δ | 121.45 | 46.8% | 2.2% | 126.04 | 48.4% | 1.9% |
| 65Δ | 120.35 | 45.9% | 1.8% | 127.74 | 52.8% | 1.7% |
| 70Δ | 119.31 | 44.2% | 1.4% | 129.45 | 57.1% | 1.5% |
| 75Δ | 118.30 | 42.0% | 1.2% | 131.34 | 58.6% | 1.2% |
| 80Δ | 117.29 | 39.9% | 0.9% | 133.33 | 58.8% | 0.9% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 115.16
- IV
- 57.0%
- B/E move
- 7.5%
25Δ
- Pseudo strike
- 129.78
- IV
- 48.9%
- B/E move
- 6.4%
- Pseudo strike
- 116.81
- IV
- 54.9%
- B/E move
- 6.4%
30Δ
- Pseudo strike
- 128.51
- IV
- 49.1%
- B/E move
- 5.7%
- Pseudo strike
- 118.45
- IV
- 52.8%
- B/E move
- 5.4%
35Δ
- Pseudo strike
- 127.24
- IV
- 49.3%
- B/E move
- 5.0%
- Pseudo strike
- 120.06
- IV
- 50.7%
- B/E move
- 4.4%
40Δ
- Pseudo strike
- 125.97
- IV
- 49.5%
- B/E move
- 4.3%
- Pseudo strike
- 121.19
- IV
- 49.6%
- B/E move
- 3.8%
45Δ
- Pseudo strike
- 124.74
- IV
- 49.4%
- B/E move
- 3.7%
- Pseudo strike
- 122.31
- IV
- 48.5%
- B/E move
- 3.3%
50Δ
- Pseudo strike
- 123.64
- IV
- 48.5%
- B/E move
- 3.2%
- Pseudo strike
- 123.44
- IV
- 47.3%
- B/E move
- 2.8%
55Δ
- Pseudo strike
- 122.55
- IV
- 47.7%
- B/E move
- 2.7%
- Pseudo strike
- 124.57
- IV
- 46.2%
- B/E move
- 2.2%
60Δ
- Pseudo strike
- 121.45
- IV
- 46.8%
- B/E move
- 2.2%
- Pseudo strike
- 126.04
- IV
- 48.4%
- B/E move
- 1.9%
65Δ
- Pseudo strike
- 120.35
- IV
- 45.9%
- B/E move
- 1.8%
- Pseudo strike
- 127.74
- IV
- 52.8%
- B/E move
- 1.7%
70Δ
- Pseudo strike
- 119.31
- IV
- 44.2%
- B/E move
- 1.4%
- Pseudo strike
- 129.45
- IV
- 57.1%
- B/E move
- 1.5%
75Δ
- Pseudo strike
- 118.30
- IV
- 42.0%
- B/E move
- 1.2%
- Pseudo strike
- 131.34
- IV
- 58.6%
- B/E move
- 1.2%
80Δ
- Pseudo strike
- 117.29
- IV
- 39.9%
- B/E move
- 0.9%
- Pseudo strike
- 133.33
- IV
- 58.8%
- B/E move
- 0.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 36.37% | |
| 36.63% | |
| 39.38% | |
| 35.63% | |
| 36.60% | |
| 35.47% | |
| 34.81% | |
| 35.86% | |
| 36.47% | |
| 37.72% | |
| 36.30% | |
| 35.38% | |
| 36.03% | |
| 36.07% | |
| 37.69% | |
| 36.59% | |
| 37.71% | |
| 37.20% | |
| 38.73% | |
| 43.73% | |
| 40.15% | |
| 40.65% | |
| 38.00% | |
| 40.43% | |
| 40.11% | |
| 38.51% | |
| 41.45% | |
| 42.64% | |
| 41.23% | |
| 41.06% | |
| 42.07% | |
| 41.27% | |
| 43.07% | |
| 43.46% | |
| 42.93% | |
| 43.29% | |
| 43.45% | |
| 48.83% | |
| 47.90% | |
| 51.89% | |
| 52.92% | |
| 42.70% | |
| 42.46% | |
| 43.05% | |
| 44.95% | |
| 44.53% | |
| 43.98% | |
| 41.12% | |
| 40.18% | |
| 40.89% | |
| 36.68% | |
| 36.79% |
Biotechnology
INMB
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease, and nonalcoholic…
More →INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases…
More →INSM
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New…
More →INVA
Description unavailable
More →IONS
Description unavailable
More →IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's…
More →